The mean of analysts' price targets for MediWound (MDWD) points to a 76.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
MediWound (MDWD) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our
MediWound (MDWD) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $1.18 per share a year ago.
Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time
MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the r
The consensus price target hints at a 134.8% upside potential for MediWound (MDWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima
MediWound (MDWD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
The consensus price target hints at a 223.1% upside potential for MediWound (MDWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima
Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Tuesday, November 21st at 8:30 am Eastern Time
MediWound (MDWD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase i
YAVNE, Israel, Sept. 05, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today
MediWound (MDWD) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of a loss of $0.41 per share. This compares to loss of $0.91 per share a year ago.
Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time
Micro-cap stocks, by definition, are stocks of companies that trade at a valuation range of $50 to $300 million. It goes without saying that investing in micro-cap stocks is a high-risk game.
YAVNE, Israel, June 14, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE